Items Tagged ‘chronic neurologic deficits’

April 24, 2013

Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis

By Logan Lafferty Logan Lafferty

Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS)… “This remyelinating antibody, if successful in clinical trials and approved, would be a novel approach to treating people with […]

View full entry

Tags: Acorda Therapeutics, antibody, chronic neurologic deficits, clinical trial, Dr. Moses Rodriguez, MS, multiple sclerosis, rHIgM22, Wall Street Journal


Contact Us · Privacy Policy